Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
- 1 November 2012
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (11) , 1861-1864
Abstract
Objective To compare the effectiveness of switching to rituximab (RTX) with switching to alternative tumour necrosis factor (TNF) antagonists in patients with rheumatoid arthritis (RA) failing on TNF antagonists. Methods A multicentre prospective 3-year observational study was performed in patients with RA treated with RTX or an alternative TNF antagonist. The baseline 28-joint disease activity score (DAS28) and Health Assessment Questionnaire (HAQ) score were compared with 6, 9 and 12 month values, adjusting for propensity score quintiles. Propensity scores were estimated for each patient using logistic regression with treatment as the dependent variable and baseline prior number of TNFs >1, years from diagnosis >5, extra-articular manifestations, previous toxicity, use of ≥2 disease-modifying antirheumatic drugs, age and sex as independent variables. Results 1124 patients were treated with either RTX (n=591, 52.6%) or alternative TNF antagonists (n=533, 47.4%). RTX-treated patients had longer disease duration (p=0.0001), larger numbers of previous TNF antagonists (pConclusions Optimal treatment for patients with RA failing on treatment with TNF antagonists may include RTX. This study suggests that the improvement in DAS28 is larger in patients treated with RTX than in those treated with monoclonal anti-TNF agents.Keywords
This publication has 7 references indexed in Scilit:
- Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysisAnnals of the Rheumatic Diseases, 2012
- Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons ApproachPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals of the Rheumatic Diseases, 2010
- B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agentsArthritis & Rheumatism, 2007
- Measuring effectiveness of drugs in observational databanks: promises and perils.Arthritis Research & Therapy, 2004
- Invited Commentary: Propensity ScoresAmerican Journal of Epidemiology, 1999
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998